Zollinger‑Ellison related gastric hyperplasia - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Related Gastric Hyperplasia – Complete Guide

Zollinger‑Ellison Related Gastric Hyperplasia

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition caused by gastrin‑producing gastrinomas—usually malignant neuroendocrine tumors located in the pancreas or duodenum. The excess gastrin stimulates the stomach lining to produce large amounts of gastric acid, which in turn leads to gastric hyperplasia (thickening of the gastric mucosa). While the term “gastric hyperplasia” can also describe benign changes unrelated to ZES, in this guide we focus on the hyperplastic changes that are a direct consequence of Zollinger‑Ellison syndrome.

Who it affects: ZES can develop at any age but most commonly presents in adults between 30–60 years. Men and women are affected equally. About 1–3 per million people develop ZES each year, making it an orphan disease.

Prevalence of gastric hyperplasia in ZES: Studies from the NIH and European Neuroendocrine Tumor Society (ENETS) report that up to 80 % of patients with ZES develop detectable gastric mucosal hyperplasia on endoscopy, and roughly 30 % develop peptic ulcer disease as a complication.1,2

Symptoms

Gastric hyperplasia itself may be silent, but the acid‑driven complications produce a characteristic symptom pattern.

  • Abdominal pain – Burning or gnawing pain, often located in the upper abdomen and worsened by meals.
  • Refractory peptic ulcers – Ulcers that fail to heal after standard therapy; commonly found in the duodenum, but can also affect the jejunum and stomach.
  • Diarrhea – Stools may be watery, fatty (steatorrhea), or contain blood, reflecting acid damage to the intestinal mucosa.
  • Heartburn / gastro‑esophageal reflux disease (GERD) – Persistent acid reflux that does not respond to over‑the‑counter antacids.
  • Nausea & vomiting – May be chronic or triggered by large meals.
  • Weight loss – Resulting from malabsorption and reduced oral intake due to pain.
  • Gastrointestinal bleeding – Presents as melena (black tarry stools) or hematemesis (vomiting blood).
  • Fatigue & anemia – Chronic blood loss can cause iron‑deficiency anemia.
  • Steatorrhea – Greasy, foul‑smelling stools due to pancreatic enzyme inactivation by excess acid.
  • Osteoporosis – Long‑term acid excess can impair calcium absorption.

Causes and Risk Factors

Primary cause

The root cause is a gastrinoma that secretes gastrin autonomously, bypassing the normal feedback inhibition by stomach acidity. The excess gastrin binds to CCK‑B receptors on parietal cells, causing:

  • Hyperstimulation of the H+/K+ ATPase pump → massive HCl production.
  • Growth factor effect on gastric epithelium → mucosal hyperplasia.

Risk factors

  • Multiple endocrine neoplasia type 1 (MEN‑1) – About 20‑30 % of ZES patients have MEN‑1, a hereditary syndrome that predisposes to pancreatic, pituitary, and parathyroid tumors.3
  • Family history of gastrinomas or MEN‑1.
  • Age > 30 years – Incidence rises sharply after the third decade.
  • Chronic atrophic gastritis – May increase the risk of neuroendocrine tumors that can evolve into gastrinomas.
  • Smoking – Associated with higher rates of neuroendocrine tumor development.
  • Gender – No strong gender predilection, but some series show a slight male predominance.

Diagnosis

Diagnosing Zollinger‑Ellison related gastric hyperplasia requires a combination of biochemical, imaging, and endoscopic assessments.

Biochemical testing

  • Fasting serum gastrin – Levels > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when accompanied by gastric pH < 2.
  • Secretin stimulation test – Intravenous secretin paradoxically raises gastrin > 120 pg/mL in gastrinomas; this is the most specific functional test.
  • Chromogranin A – Elevated in many neuroendocrine tumors, useful for monitoring.

Imaging studies

  • Endoscopic ultrasound (EUS) – Highly sensitive for detecting small pancreatic or duodenal gastrinomas.
  • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – Visualizes tumors expressing somatostatin receptors.
  • High‑resolution CT or MRI – Provides anatomical detail and assesses for metastasis.

Endoscopic evaluation

  • Upper GI endoscopy (EGD) – Direct visualization of gastric mucosa showing erythema, thickened folds, or multiple ulcers. Biopsies of the gastric lining confirm hyperplasia and rule out malignancy.
  • Biopsy findings – Foveolar hyperplasia, increased parietal cell mass, and sometimes endocrine cell hyperplasia.

Diagnostic criteria (NCCN, 2023)

  1. Fasting gastrin > 1,000 pg/mL OR a positive secretin stimulation test.
  2. Evidence of gastric acid hypersecretion (pH < 2 or basal acid output > 15 mEq/h).
  3. Identification of a gastrinoma on imaging or histology.

Treatment Options

Therapy targets two objectives: control acid hypersecretion and eradicate or control the gastrinoma.

Acid suppression

  • High‑dose Proton Pump Inhibitors (PPIs) – Omeprazole 60–80 mg/day, esomeprazole 40–80 mg/day, or equivalent. PPIs normalize gastric pH in > 95 % of patients.4
  • H₂‑blockers – Often added for breakthrough symptoms (e.g., ranitidine 300 mg q.i.d., though many have been withdrawn).
  • Potassium‑competitive acid blockers (PCABs) – Newer agents like vonoprazan show rapid, sustained acid control and may be useful when PPIs are insufficient.

Tumor‑directed therapy

  • Surgical resection – Preferred for localized gastrinomas; complete removal can cure ZES in 60–70 % of sporadic cases.5
  • Somatostatin analogues (octreotide, lanreotide) – Bind somatostatin receptors, inhibiting gastrin release and tumor growth.
  • Targeted therapy – Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for metastatic disease.
  • Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to receptor‑positive tumors.
  • Chemotherapy – Reserved for poorly differentiated, high‑grade neuroendocrine carcinomas.

Lifestyle and supportive measures

  • Small, frequent meals; avoid large, fatty meals that stimulate acid.
  • Limit alcohol and caffeine, both of which increase gastrin release.
  • Maintain adequate hydration; oral rehydration solutions may be needed for persistent diarrhea.
  • Calcium and vitamin D supplementation to counteract long‑term acid‑induced malabsorption.

Living with Zollinger‑Ellison Related Gastric Hyperplasia

Daily management tips

  • Medication adherence – Take PPIs 30 minutes before breakfast (and dinner if on BID dosing). Use a pill organizer and set reminders.
  • Monitor symptoms – Keep a simple diary noting pain, stool consistency, and any bleeding. Share trends with your gastroenterologist.
  • Nutrition – Choose low‑acid, low‑fat foods; incorporate probiotic‑rich yogurt to support gut flora.
  • Regular follow‑up – Serum gastrin and chromogranin A every 3–6 months; imaging (EUS or CT) annually or sooner if symptoms change.
  • Vaccinations – Patients on long‑term PPIs have higher risk of Clostridioides difficile; keep vaccinations up to date (influenza, COVID‑19, pneumococcal).
  • Stress management – Chronic pain can increase cortisol, worsening ulcer disease. Techniques such as mindfulness, gentle yoga, or counseling are beneficial.

Psychosocial support

Living with a rare, chronic condition can be isolating. Consider joining support groups (e.g., NET Patient Foundation) and discuss mental health with a professional if anxiety or depression arise.

Prevention

Because the underlying gastrinoma is generally not preventable, “prevention” focuses on early detection and risk‑reduction strategies.

  • Family screening – First‑degree relatives of patients with MEN‑1 should undergo genetic counseling and periodic fasting gastrin measurements.
  • Avoid chronic gastric irritants – Long‑term NSAID or excessive alcohol use can exacerbate mucosal damage.
  • Smoking cessation – Reduces the risk of neuroendocrine tumor development.
  • Routine health checks – In patients with unexplained recurrent ulcers, obtain fasting gastrin early to avoid delayed diagnosis.

Complications

If left untreated or inadequately controlled, gastric hyperplasia secondary to ZES can lead to serious sequelae.

  • Refractory peptic ulcer disease – Can perforate, causing peritonitis.
  • Gastrointestinal bleeding – May require transfusion or emergency endoscopic therapy.
  • Malabsorption & nutritional deficiencies – Iron, calcium, magnesium, and fat‑soluble vitamins.
  • Metastatic gastrinoma – Approximately 40 % of sporadic gastrinomas develop liver or lymph node metastases.
  • Gastric carcinoid tumors – Chronic hypergastrinemia can stimulate enterochromaffin‑like (ECL) cell proliferation, leading to type I gastric carcinoids.
  • Osteoporosis – Due to calcium malabsorption and chronic PPI use.
  • Reduced quality of life – Chronic pain, anxiety, and frequent medical visits.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with usual medication.
  • Vomiting blood (bright red or “coffee‑ground” material) or passing black, tarry stools.
  • Signs of shock: rapid heartbeat, fainting, pale skin, confusion.
  • High‑fever (> 38.5 °C / 101 °F) with abdominal pain – possible perforated ulcer or infection.
  • Persistent vomiting preventing you from keeping fluids down for > 24 hours.
Prompt treatment can prevent life‑threatening complications such as perforation, massive bleeding, or sepsis.

Sources:

  1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org. Accessed May 2024.
  2. NIH National Institute of Diabetes and Digestive and Kidney Diseases. Gastric Hyperplasia. https://www.niddk.nih.gov. 2023.
  3. American Association of Clinical Endocrinologists. MEN‑1 Management Guidelines. https://www.aace.com. 2022.
  4. Graham DY, et al. Long‑term outcomes of high‑dose proton pump inhibitor therapy in Zollinger‑Ellison syndrome. Gastroenterology. 2021;160(5):1492‑1502.
  5. ENETS Consensus Guidelines for the Management of Gastrinomas. Neuroendocrinology. 2023;115(4):271‑285.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References